-
-
GLIVEC 100mg (imatinib mesylate) ₨ 80,400
Glivec (imatinib mesylate) is indicated for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
-
GLIVEC 400mg (imatinib mesylate) ₨ 142,000
Glivec (imatinib mesylate) is indicated for the treatment of newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
-
Jakavi 15mg (Ruxolitinib) ₨ 547,392
Jakavi is indicated for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.
-
Jakavi 5mg (Ruxolitinib) ₨ 217,000
Jakavi is indicated for the treatment of adult patients with polycythemia vera who are resistant to or intolerant of hydroxyurea.
-
KISQALI 200mg (ribociclib) ₨ 577,884
KISQALI is indicated for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer.
-
TASIGNA 150mg (nilotinib) ₨ 125,400
Tasigna 200mg (nilotinib) is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with
newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. -
TASIGNA 200mg (nilotinib) ₨ 117,040
Tasigna 200mg (nilotinib) is indicated for the treatment of adult and pediatric patients greater than or equal to 1 year of age with
newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
Afinitor 10mg (everolimus)
₨ 495,000
GLIVEC 100mg (imatinib mesylate)
₨ 80,400
GLIVEC 400mg (imatinib mesylate)
₨ 142,000
Jakavi 15mg (Ruxolitinib)
₨ 547,392
Jakavi 5mg (Ruxolitinib)
₨ 217,000
KISQALI 200mg (ribociclib)
₨ 577,884
TASIGNA 150mg (nilotinib)
₨ 125,400
TASIGNA 200mg (nilotinib)
₨ 117,040
